This month’s Science Matters column in START-UP looks at a recent assessment of characteristics of the clinical trials recorded in the ...

"If you guys were the inventors of regorafenib, you'd have invented regorafenib." It may not have much of a r...

By Richard Gliklich , MD, President and CEO, Outcome We all know, broadly speaking, the mission of comparative effectiveness research (CER)...

The first public presentation of data from the National Eye Institute’s head-to-head study of Lucentis vs. Avastin in macular degeneration w...

OK – the title is a bit of a come-on, I’ll admit. Still, there’s a certain logic to it, if you’ll just bear with me. To start with the sex...

Somewhere, Senate Finance Committee Chairman Max Baucus (D-Mt.) is smiling. Baucus may be making inroads on his effort to relabel comparativ...

It's tough times for biotech investors, not much disagreement there. But in covering one of the deals of the week, we found a bright spo...

There is plenty of interest in industry in the question of who, exactly, will be overseeing the launch of a new federal comparative effectiv...

The debate over a federal comparative effectiveness research institute in the US was one of the big issues for biopharma companies early in ...

The Agency for Health Care Research & Quality (the US government's de facto comparative effectiveness research center) is slowly but...

Are you sitting down? The FDA is practicing stealth comparative effectiveness. Or at least that's one of the claims to come out of a liv...

The Food & Drug Administration's public health alert on Plavix is, as we point out in "The Pink Sheet" DAILY , a nice boos...